You just read:

CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting

News provided by

CTI BioPharma Corp.

Nov 21, 2016, 16:01 ET